Matthew D. Galsky, MD, on How Data in Neoadjuvant Therapy May Inform Future Research Across Tumor Types

Video

CancerNetwork® spoke with Matthew D. Galsky, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss leading data to come out of the meeting and what it means for the future of cancer systemic therapy.

CancerNetwork® sat down with Matthew D. Galsky, MD, to discuss some of the data to come out of the American Association for Cancer Research (AACR) Annual Meeting 2021 that offer the greatest promise to the cancer treatment paradigm going forward. Interestingly, Galsky cited data regarding neoadjuvant therapy in the lung cancer setting as a promising indicator for future research in the genitourinary space.

Transcription:

One of the more interesting findings from a genitourinary oncologist’s standpoint is an observation from a lung cancer study that [looked at] neoadjuvant chemotherapy plus immune checkpoint blockade. [It showed] with the combination of immune checkpoint blockade plus chemotherapy a much higher pathologic complete response rate compared with chemotherapy alone. Again, that reinforces this concept of whether what we’re observing in metastatic urothelial cancer is a function of the chemotherapy backbone or that lung cancer and bladder cancer are just very different diseases, and we won’t see the same thing.

But the reason that the neoadjuvant lung cancer study is important to us in the field is that we have a number of ongoing neoadjuvant studies combining cisplatin-based chemotherapy with PD-1 or PD-L1 blockade for patients with muscle-invasive bladder cancer. If that is a hint of what we might see in bladder cancer as well, where the chemotherapy backbone in the neoadjuvant study is homogeneous and there isn’t this issue of carboplatin, hopefully we’ll see similar results in bladder cancer because we haven’t had new neoadjuvant chemotherapy regimens in this disease in decades.

Recent Videos
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content